• UCLA Health
  • myUCLAhealth
  • School of Medicine
Radiation Oncology UCLA

UCLA Radiation Oncology

Radiation Oncology UCLA
  • About Us
    • Chair's Welcome
    • Request an Appointment
    • Refer a Patient
    • Contact Us
    • How You Can Help
  • Our Team
  • Patients & Treatments
    • First Visit for Patients
    • Patient Education Video
    • FAQs
    • Patient Stories
    • Testimonials
    • Treatments
    • Resources / Links
    • Clinical Trials
    • Request an Appointment
    • Health Plans
    • Contact Us
  • Research & Technologies
    • Innovation & Technology
    • Cutting-Edge Devices
    • Division of Molecular and Cellular Oncology
    • Medical Physics Research
    • Translational Research
    • Scholarly Activity
    • Clinical Trials
  • Education & Training
    • Welcome and Overview
    • Residency Recruitment 2020
    • Medical Residency
    • Residents
    • Medical Physics Residency Program
    • Medical Student Rotation
    • Brachytherapy Fellowship Program
    • Medical Student Preceptorship Program
    • BioMedical Physics Graduate Program
    • Conferences & Courses
  • News & Events
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Radiation Oncology

Cardiac SABR

  1. Home
  2. Patients & Treatments
  3. Clinical Trials
  4. Cardiac SABR

Cardiac SABR

A Novel, Experimental Therapy for Dangerous Abnormal Heart Rhythms

Clinical Trial:  Cardiac Arrhythmias

Stereotactic Ablative Radiotherapy in Cardiac Arrhythmias

Interventional Trial: Stereotactic Ablative Radiotherapy of Refractory Ventricular Tachycardia – a Phase I/II Study

Basic Information

This study is designed for patients with ventricular tachycardia (VT) resulting in dangerous abnormal heart rhythms for whom routine therapies have been unsuccessful.  Subjects who enroll will receive stereotactic ablative radiotherapy (SABR), a therapy routinely used in cancer patients with minimal side effects.  It is hoped that a 30 minute session of SABR will control VT in these individuals.   

Research Procedures:

The study will be done in two parts.  Part 1 is designed to determine the highest safely tolerated dose of radiation to the heart.  Part 2 is designed to determine the effectiveness of this dose to control this abnormal rhythm.

Each patient will be seen at Radiation Oncology and undergo a CT scan for planning of their radiation therapy.  Each subject will receive a 30 minute session of SABR, and will be asked to return to both their cardiologist and UCLA Radiation Oncology on a regular, routine basis for check-up visits for up to five years.  

Eligibility Criteria (Not a complete list):

Basic Inclusion Criteria

  • Documented sustained ventricular arrhythmias refractory to or not a suitable candidate for catheter based RFA ablative therapy, cardiac sympathetic denervation therapy, cardiac transplantation, other additional medical management
  • Pacemaker in place with documented episodes of recurrent VT despite best clinical management If ischemic cardiomyopathy, myocardial infarction occurred more than one month prior to enrollment
  • No history of prior radiotherapy to the chest

Other eligibility criteria exist

For More Detailed Information Contact:

  • Robert K. Chin, M.D., Ph.D. Principal Investigator       (310) 825- 9775
  • Vicky Ramirez, Study Coordinator                                 (310) 267-8996                        
  • UCLA Department of Radiation Oncology                    (310) 206-6577
Facebook Twitter Instagram Youtube LinkedIn
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 310-825-9775
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap